

### REMARKS

Claims 1, 2, 15-23, 33, 34, 50, 51, 106, 109, and 112 are currently pending in the application. Claims 3-14, 24-32, 35-49, 52-105, 107, 108, 110, and 111 have been canceled and claims 1, 15, 16, 17, 19, 21, 22, 51, 106, and 109 have been amended without prejudice or disclaimer, solely for the purpose of expediting patent prosecution in accordance with the U.S. Patent Office Business Goals (65 Fed. Reg. 54604 (September 8, 2000)). Applicants reserve the right to present any cancelled subject matter in a copending application.

Amended claim 1 recites: “[a] method of treating cancer...” (see, *inter alia*, page 9, lines 10-14; page 18, lines 27-32 to page 19, lines 1-6; page 19, lines 7-32 to page 20, lines 1-25; page 75, lines 1-3; page 75, lines 15-29 of the application as originally filed).

Amended claim 15 recites: “carboplatin” (see, *inter alia*, page 74, list number 39 of the application as originally filed).

Amended claim 16 recites: “irenotecan” (see, *inter alia*, page 73, list number 20; and page 93, lines 1-5 of the application as originally filed).

Amended claim 17 recites: “capecitabine” (see, *inter alia*, page 73, list number 8 of the application as originally filed).

Amended claim 19 recites: “a hormonal agent” (see, *inter alia*, page 8, line 10 of the application as originally filed).

Amended claim 21 recites: “a biologic agent selected from” (see, *inter alia*, page 63, lines 19-32 to page 65, lines 1-24; and page 74, list numbers 47-54 of the application as originally filed).

Amended claim 22 recites: “wherein the biologic agent” and “trastuzumab” (see, *inter alia*, page 64, lines 13-18 of the application as originally filed).

Amended claim 51 recites exemplary cancers (see, *inter alia*, page 6, lines 5-23; page 19, lines 7-25; page 23, lines 27-28; page 60, lines 2-7; page 61, lines 15-17; page 62, lines 2-12; page 63, lines 2-11; page 64, lines 11-15; page 65, lines 18-23; and page 89, lines 1-32 to page 92, lines 1-11 of the application as originally filed).

Amended claim 106 recites: “[a] method of selectively inducing terminal differentiation...” (see, *inter alia*, page 9, lines 10-14; page 13, lines 18-25; page 18, lines 27-32 to page 19, lines 1-6; page 19, lines 7-32 to page 20, lines 1-25; page 75, lines 1-3; page 75, lines 15-29 of the application as originally filed).

Amended claim 109 recites: “[a]n *in vitro* method...” (see, *inter alia*, page 9, lines 10-14; page 13, lines 26-32; page 18, lines 27-32 to page 19, lines 1-6; page 19, lines 7-32 to page 20, lines 1-25; page 75, lines 1-3; page 75, lines 15-29 of the application as originally filed).

New claim 112 recites: “[a] pharmaceutical composition...” (see, *inter alia*, page 6, lines 28-30 of the application as originally filed).

These amendments and newly added claim are supported by the application as originally filed, and do not constitute new matter. Support is shown in parentheses, above. Entry of these amendments is respectfully requested.

**CONCLUSION**

Prompt examination of the application is respectfully requested. Although no additional charges are believed to be due, the Commission is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's Deposit Account Number **50-0311**, Reference Number **24852-501 CIP5 NATL**, Customer Number **35437**. If the Examiner is of the opinion that further discussion of this Amendment would be helpful, the Examiner is hereby respectfully requested to telephone the Applicants' undersigned representative at the telephone number provided below.

Date: February 10, 2006

Respectfully submitted,



---

Ivor R. Elrifi, Reg. No. 39,529  
Caryn DeHoratius, Reg. No. 45,881  
Attorneys for Applicants  
MINTZ, LEVIN, COHN, FERRIS, *et al.*  
666 Third Avenue, 24th Floor  
New York, New York 10017  
Telephone: (212) 935-3000  
Telefax: (212) 983-3115